Comparative Pharmacology
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE versus DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE versus DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER.
DOBUTAMINE HYDROCHLORIDE vs DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dobutamine directly stimulates β1-adrenergic receptors in the heart, increasing myocardial contractility and stroke volume with minimal chronotropic effect at therapeutic doses. It also has mild β2 and α1 activity.
Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-1 adrenergic receptors of the heart, increasing contractility and cardiac output. It also has mild beta-2 and alpha-1 receptor activity.
Intravenous infusion: 2.5-20 mcg/kg/min, titrated to hemodynamic response. Typical starting dose 2.5-5 mcg/kg/min.
Continuous IV infusion: 2.5 to 20 mcg/kg/min; titrate to desired hemodynamic response. Maximum dose: 40 mcg/kg/min.
None Documented
None Documented
2-3 minutes (short distribution half-life). Terminal elimination half-life is approximately 2 minutes. Clinical context: Requires continuous intravenous infusion for sustained effect due to rapid clearance.
Terminal elimination half-life is approximately 2 minutes for the parent drug (dobutamine) due to rapid metabolism by COMT. In clinical context, the effect half-life is about 2–3 minutes, requiring continuous intravenous infusion to maintain steady-state concentrations.
Primarily renal (90-95% as inactive metabolites, mainly glucuronide conjugates and 3-O-methyl metabolites). Less than 5% excreted unchanged. Biliary/fecal elimination is minimal (<5% in feces).
Primarily renal excretion of metabolites (catechol-O-methyltransferase conjugates) and unchanged drug: approximately 80% renal, 20% biliary/fecal. Less than 5% excreted unchanged in urine.
Category C
Category C
Inotropic Agent
Inotropic Agent